Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Baxter
Mallinckrodt
Medtronic
Dow

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ABIRATERONE ACETATE

➤ Subscribe for complete access

« Back to Dashboard

505(b)(2) Clinical Trials for abiraterone acetate

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT01845792 ↗ Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer Terminated Janssen Services, LLC Phase 2 2013-07-01 Patients are being asked to take place in this research study because they have advanced prostate cancer that has gotten worse after other treatments. If they join this study they will receive a new combination of drugs that are used to treat prostate cancer.
New Combination NCT01845792 ↗ Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer Terminated University of Colorado, Denver Phase 2 2013-07-01 Patients are being asked to take place in this research study because they have advanced prostate cancer that has gotten worse after other treatments. If they join this study they will receive a new combination of drugs that are used to treat prostate cancer.
New Formulation NCT01897389 ↗ A Study to Assess the Relative Bioavailability of 4 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Participants Completed Janssen Research & Development, LLC Phase 1 2013-07-01 The purpose of this study is to evaluate the relative bioavailability of 4 new formulations of abiraterone acetate compared to the current commercial formulation.
New Formulation NCT04887506 ↗ TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer Recruiting Tavanta Therapeutics Phase 3 2021-04-14 The purpose of this study is to investigate the safety and efficacy of a new formulation of an existing drug product called TAVT-45 in patients with metastatic prostate cancer.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for abiraterone acetate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00473512 ↗ A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy Completed Cougar Biotechnology, Inc. Phase 1/Phase 2 2005-11-01 The purpose of this study is to determine the maximum tolerated dose and evaluate the safety, tolerability, and activity at the recommended dose (maximum tolerated dose [MTD]) of abiraterone acetate (also known as CB7630) in participants with hormone refractory prostate (gland that makes fluid that aids movement of sperm) cancer (HRPC).
NCT00473746 ↗ Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer Completed Janssen Research & Development, LLC Phase 1/Phase 2 2006-06-01 The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activities of abiraterone acetate (also referred to as CB7630) in patients with hormone refractory prostate cancer (HRPC).
NCT00474383 ↗ An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy Completed Cougar Biotechnology, Inc. Phase 2 2006-11-01 The purpose of this study is to assess the anti-tumor activities and safety of abiraterone acetate in participants with prostate cancer (a disease in which cells in the prostate gland [a gland in the male reproductive system found below the bladder and in front of the rectum] become abnormal and start to grow uncontrollably, forming tumors) who have failed taxane (docetaxel)-based chemotherapy.
NCT00485303 ↗ An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy Completed Cougar Biotechnology, Inc. Phase 2 2007-06-01 The purpose of this study is to evaluate the efficacy and safety of abiraterone acetate in participants with advanced prostate cancer (a disease in which cells in the prostate gland become abnormal and start to grow uncontrollably, forming tumors).
NCT00544440 ↗ An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma Completed Janssen Research & Development, LLC Phase 2 2007-10-01 The purpose of this study is to investigate the effect of abiraterone acetate on levels of androgens and steroid metabolites in bone marrow plasma of patients with metastatic castration-resistant prostate cancer (CRPC).
NCT00600535 ↗ A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer Completed Cougar Biotechnology, Inc. Phase 1 2007-07-01 The purpose of this study is to evaluate the pharmacokinetics (how the drug concentrations change over time) of capsule and tablet formulations of CB7630 (abiraterone acetate) taken with and without food in patients with prostate cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for abiraterone acetate

Condition Name

Condition Name for abiraterone acetate
Intervention Trials
Prostate Cancer 87
Prostatic Neoplasms 17
Metastatic Castration-Resistant Prostate Cancer 16
Prostate Neoplasms 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for abiraterone acetate
Intervention Trials
Prostatic Neoplasms 200
Adenocarcinoma 25
Carcinoma 18
Prostatic Neoplasms, Castration-Resistant 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for abiraterone acetate

Trials by Country

Trials by Country for abiraterone acetate
Location Trials
Canada 126
United Kingdom 84
Spain 81
Japan 77
France 67
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for abiraterone acetate
Location Trials
California 76
New York 64
Texas 59
Maryland 47
Michigan 42
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for abiraterone acetate

Clinical Trial Phase

Clinical Trial Phase for abiraterone acetate
Clinical Trial Phase Trials
Phase 4 7
Phase 3 31
Phase 2/Phase 3 1
[disabled in preview] 176
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for abiraterone acetate
Clinical Trial Phase Trials
Completed 91
Recruiting 54
Active, not recruiting 47
[disabled in preview] 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for abiraterone acetate

Sponsor Name

Sponsor Name for abiraterone acetate
Sponsor Trials
Janssen Research & Development, LLC 37
National Cancer Institute (NCI) 33
Cougar Biotechnology, Inc. 12
[disabled in preview] 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for abiraterone acetate
Sponsor Trials
Industry 199
Other 186
NIH 35
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Baxter
McKinsey
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.